查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1673491

全球心源性休克市场：规模、趋势、COVID-19 影响分析以及按治疗类型、最终用户和地区分類的 2030 年预测

Global Cardiogenic Shock Market: Analysis By Treatment Type (Drugs, Mechanical Circulatory Support Devices and Others), By End User, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030
出版日期: | 出版商: Daedal Research | 英文 147 Pages | 订单完成后即时交付

价格

心源性休克是一种危及生命的疾病，患者心臟突然无法泵出足够的血液来满足身体的需求。它最常见的原因是严重心臟病发作（心肌梗塞），但也可能由其他心臟疾病引起，如心臟衰竭、心律不整、心肌炎和瓣膜疾病。预计2024年全球心源性休克市场规模为35.7亿美元，到2030年将达52亿美元。

由于心血管疾病（CVD）盛行率不断上升、先进机械循环支援设备的采用不断增加以及对早期诊断和治疗认识的不断提高，全球心源性休克市场预计将大幅增长。老年人口的快速增加，以及心臟病的挥发性，进一步加速了市场的扩张。经皮辅助人工心臟(pVAD) 和体外膜氧合 (ECMO) 等治疗方案的技术进步正在提高患者的生存率并推动需求。此外，医疗成本的上涨、优惠的报销政策以及新治疗方法临床试验数量的增加也促进了市场的成长。人工智慧与诊断工具和即时监测系统的整合也正在改善治疗效果，进一步推动全球心源性休克市场的发展。金额2025-2030 年预测期内全球心源性休克市场复合年增长率为 6.47%。

本报告对全球心源性休克市场进行了深入分析，并提供了有关市场动态、COVID-19 的影响和竞争格局的资讯。

目录

第一章执行摘要

第 2 章 简介

  • 心源性休克：概述
    • 心源性休克简介
    • 如何降低心源性休克的风险
  • 心源性休克的细分：概述
    • 心源性休克的细分

第三章 全球市场分析

  • 全球心源性休克市场：分析
    • 全球心源性休克市场概览
    • 全球心源性休克市场规模
    • 全球心源性休克市场（依治疗类型）
    • 全球心源性休克市场（依最终用户划分）
    • 全球心源性休克市场（按区域）
  • 全球心源性休克市场：治疗类型分析
    • 全球心源性休克市场概览（依治疗类型）
    • 药物性心源性休克治疗的全球市场规模
    • 使用机械循环支援 (MCS) 设备进行心源性休克治疗的全球市场规模
    • 全球其他心源性休克市场规模
  • 全球心源性休克市场：最终用户分析
    • 全球心源性休克市场：最终用户概览
    • 医院和诊所心源性休克的全球市场规模
    • 专门心臟中心心源性休克的全球市场规模
    • 全球门诊手术中心心源性休克市场规模
    • 全球其他心源性休克市场规模

第四章 区域市场分析

  • 北美心源性休克市场：分析
    • 北美心源性休克市场概览
    • 北美心源性休克市场规模
    • 北美心源性休克市场（按地区）
    • 美国心源性休克市场规模
    • 加拿大心源性休克市场规模
    • 墨西哥心源性休克市场规模
  • 欧洲心源性休克市场：分析
    • 欧洲心源性休克市场概况
    • 欧洲心源性休克市场规模
    • 欧洲心源性休克市场（按地区）
    • 德国心源性休克市场规模
    • 英国心源性休克市场规模
    • 法国心源性休克市场规模
    • 义大利心源性休克市场规模
    • 西班牙心源性休克市场规模
    • 其他欧洲心源性休克市场规模
  • 亚太心源性休克市场分析
    • 亚太地区心源性休克市场概览
    • 亚太心源性休克市场规模
    • 亚太地区心源性休克市场（按区域）
    • 中国心源性休克市场规模
    • 日本心源性休克市场规模
    • 印度心源性休克市场规模
    • 韩国心源性休克市场规模
    • 其他亚太地区心源性休克市场规模
  • 拉丁美洲心源性休克市场：分析
    • 拉丁美洲心源性休克市场概况
    • 拉丁美洲心源性休克市场规模
  • 中东和非洲心源性休克市场分析
    • 中东和非洲心源性休克市场概况
    • 中东和非洲心源性休克市场规模

第五章 新冠肺炎疫情的影响

  • COVID-19 对全球心源性休克市场的影响
  • COVID-19 对全球心源性休克市场的影响

第六章 市场动态

  • 成长动力
    • 世界老龄人口不断增长
    • 心臟疾病率增加
    • 医疗费用上涨
    • 久坐生活方式盛行
    • 提高认识和早期诊断
  • 任务
    • 先进治疗和设备成本高昂
    • 缺乏熟练的医护人员
  • 市场趋势
    • 人工智慧的采用率不断提高
    • 机械循环支援 (MCS) 设备的技术进步
    • 新型药物疗法的开发
    • 增加研发活动
    • 采用微创技术
    • 对照护现场（POC）检测的需求不断增加

第七章 竞争格局

  • 全球心源性休克市场公司：最新发展

第八章 公司简介

  • Abbott
  • Medtronic plc
  • Boston Scientific Corporation
  • AstraZeneca Plc
  • Roche Holdings AG
  • Bayer AG
  • Getinge
  • Johnson & Johnson (Abiomed)
  • Viatris, Inc.
  • Terumo Corporation
  • Endo International plc (Par Pharmaceutical)
  • Windtree Therapeutics, Inc.
  • ZOLL Medical Corporation

Cardiogenic shock is a life-threatening condition in which the heart suddenly fails to pump enough blood to meet the body's needs. It is most commonly caused by a severe heart attack (myocardial infarction) but can also result from other heart conditions such as heart failure, arrhythmias, myocarditis, or valve disorders. The global cardiogenic shock market value in 2024 stood at US$3.57 billion, and is projected to reach US$5.20 billion by 2030.

The global cardiogenic shock market is poised for significant growth, driven by the rising prevalence of cardiovascular diseases (CVDs), increasing adoption of advanced mechanical circulatory support devices, and growing awareness regarding early diagnosis and treatment. The surge in aging populations, who are more prone to heart-related conditions, further accelerates market expansion. Technological advancements in treatment options, such as percutaneous ventricular assist devices (pVADs) and extracorporeal membrane oxygenation (ECMO), are improving patient survival rates and driving demand. Additionally, increasing healthcare expenditures, favorable reimbursement policies, and the rising number of clinical trials for novel therapies contribute to market growth. The integration of artificial intelligence (AI) in diagnostic tools and real-time monitoring systems is also enhancing treatment outcomes, further boosting the global cardiogenic shock market. The global cardiogenic shock market value is projected to grow at a CAGR of 6.47%, during the forecast period of 2025-2030.

Market Segmentation Analysis:

By Treatment Type: According to the report, the global cardiogenic shock market is bifurcated into three segments based on the treatment type: drugs, mechanical circulatory support (MCS) devices and others. Drugs segment acquired majority of share in the market in 2024 due to the widespread use of vasopressors, inotropes, and anticoagulants as first-line treatments to stabilize patients and restore hemodynamic function. These medications are readily available, cost-effective, and crucial for immediate management, contributing to their significant market share. However, the mechanical circulatory support (MCS) devices segment is expected to grow the fastest due to the increasing adoption of advanced life-saving technologies such as intra-aortic balloon pumps (IABPs), percutaneous ventricular assist devices (pVADs), and extracorporeal membrane oxygenation (ECMO). These devices offer superior efficacy in maintaining cardiac output and reducing mortality rates in severe cardiogenic shock cases, especially when drug therapy alone is insufficient. Additionally, continuous technological advancements, increasing clinical evidence supporting their benefits, and growing healthcare investments in critical care infrastructure are fueling the rapid expansion of the MCS devices segment.

By End-user: According to the report, the global cardiogenic shock market is bifurcated into four types of end-users: hospitals & clinics, specialty cardiac centers, ambulatory surgical centers and others. Hospitals segment acquired the majority share in the global cardiogenic shock market in 2024 and is also the fastest-growing segment due to the high patient influx, availability of advanced treatment options, and presence of specialized cardiac care units. Hospitals are the primary centers for managing cardiogenic shock, offering 24/7 emergency care, intensive monitoring, and access to life-saving interventions such as mechanical circulatory support (MCS) devices, extracorporeal membrane oxygenation (ECMO), and catheter-based procedures. The increasing number of hospital admissions due to the rising prevalence of cardiovascular diseases (CVDs) and the growing elderly population further drive this segment's growth. Additionally, hospitals benefit from higher healthcare investments, government funding, and favorable reimbursement policies. The expansion of multi-specialty hospitals and the rising focus on improving critical care infrastructure further contribute to the segment's rapid growth in the global cardiogenic shock market.

By Region: The report provides insight into the cardiogenic shock market based on the geographical operations, namely, North America, Europe, Asia Pacific and rest of the world. North America cardiogenic shock market enjoyed the highest market share in 2024 due to its well-established healthcare infrastructure, high prevalence of cardiovascular diseases (CVDs), and widespread adoption of advanced treatment options. The region also benefits from strong government initiatives, favorable reimbursement policies, and extensive research and development activities aimed at improving cardiogenic shock management. However, the Asia Pacific market is expected to grow the fastest during the forecast period due to the rising incidence of cardiovascular diseases, increasing healthcare expenditure, and improving access to advanced medical treatments. Rapid urbanization, a growing aging population, and lifestyle changes leading to higher risk factors such as diabetes and hypertension further contribute to market expansion. Additionally, the region is witnessing significant investments in healthcare infrastructure, an increasing number of specialized cardiac centers, and greater awareness about early diagnosis and treatment of cardiogenic shock, driving its rapid growth.

Global Cardiogenic Shock Market Dynamics:

Growth Drivers: One of the most important factors driving the growth of global cardiogenic shock market is increase in the global geriatric population. The increasing global geriatric population is a key driver of growth in the cardiogenic shock market, as aging is a major risk factor for cardiovascular diseases (CVDs), including heart attacks, heart failure, and cardiogenic shock. Older adults are more likely to develop comorbidities such as hypertension, diabetes, and atherosclerosis, which contribute to cardiac complications and increase the likelihood of cardiogenic shock. With advancements in healthcare extending life expectancy, the number of elderly individuals requiring critical cardiac care is rising, driving demand for both pharmaceutical and mechanical interventions. Other factors driving the growth of global cardiogenic shock market include increasing incidence of heart disease, growing healthcare expenditure, growing prevalence of sedentary lifestyle, rising awareness and early diagnosis etc.

Challenges: One significant challenge faced by the global cardiogenic shock market is high cost of advanced therapies and devices. The high cost of advanced therapies and mechanical circulatory support (MCS) devices poses a significant challenge to the growth of the global cardiogenic shock market. Treatments such as extracorporeal membrane oxygenation (ECMO), percutaneous ventricular assist devices (pVADs), and intra-aortic balloon pumps (IABPs) are highly effective but come with substantial costs, making them less accessible, especially in low- and middle-income countries. The expenses associated with these technologies include not only the initial procurement but also ongoing maintenance, specialized healthcare personnel, and intensive post-procedure care, further increasing the financial burden on healthcare systems and patients. Another challenge might include shortage of skilled staff etc.

Trends: The adoption of minimally invasive techniques is a significant trend in the global cardiogenic shock market due to their ability to improve patient outcomes while reducing recovery time, complications, and hospital stays. Procedures such as percutaneous coronary intervention (PCI), percutaneous ventricular assist devices (pVADs), and catheter-based extracorporeal membrane oxygenation (ECMO) offer effective support for patients in cardiogenic shock with less trauma compared to traditional open-heart surgeries. These techniques allow for quicker stabilization of patients, leading to lower mortality rates and improved long-term prognosis. Additionally, advancements in interventional cardiology, along with the increasing preference for minimally invasive procedures among physicians and patients, are driving their widespread adoption. The growing availability of specialized catheter-based interventions and the expansion of hybrid operating rooms in hospitals further support this trend. The market is also projected to grow at a fast pace during the forecast period, due to various other latest trends such as rise in adoption of artificial intelligence, technological advancements, development of novel pharmacological therapies, rise in research and development activities, rising demand for point-of-care testing etc.

Impact Analysis of COVID-19 and Way Forward:

The COVID-19 pandemic initially disrupted the global cardiogenic shock market due to delays in non-emergency cardiac procedures, strained healthcare resources, and supply chain challenges. However, post-COVID-19, the market rebounded with increased investments in critical care infrastructure, growing awareness of cardiovascular complications linked to COVID-19, and accelerated adoption of advanced treatment modalities.

Competitive Landscape and Recent Developments:

The global cardiogenic shock market is characterized by a moderately consolidated landscape, with a few dominant players holding significant market shares, while smaller companies also contribute to the market dynamics. Key players of global cardiogenic shock market are:

Abbott

Medtronic plc

Boston Scientific Corporation

AstraZeneca Plc

Roche Holdings AG

Bayer AG

Getinge

Johnson & Johnson (Abiomed)

Viatris Inc.

Terumo Corporation

Endo International plc (Par Pharmaceutical)

Windtree Therapeutics Inc.

ZOLL Medical Corporation

The key players are constantly investing in strategic initiatives, such as adoption of new technologies, introducing their products to emerging markets and more, to maintain a competitive edge in this market. For instance, In October 2024, Abbott announced the initiation of the TEAM-HF clinical trial, a groundbreaking study designed to improve outcomes for patients with worsening heart failure and In January 2024, Windtree Therapeutics announced a licensed agreement with Lee's Pharmaceuticals to develop and commercialize a positive inotropic agent called Istraoxime to improve systolic and diastolic cardiac function.

Table of Contents

1. Executive Summary

2. Introduction

  • 2.1 Cardiogenic Shock: An Overview
    • 2.1.1 Introduction to Cardiogenic Shock
    • 2.1.2 Ways to Reduce Cardiogenic Shock Risk
  • 2.2 Cardiogenic Shock Segmentation: An Overview
    • 2.2.1 Cardiogenic Shock Segmentation

3. Global Market Analysis

  • 3.1 Global Cardiogenic Shock Market: An Analysis
    • 3.1.1 Global Cardiogenic Shock Market: An Overview
    • 3.1.2 Global Cardiogenic Shock Market by Value
    • 3.1.3 Global Cardiogenic Shock Market by Treatment Type
    • 3.1.4 Global Cardiogenic Shock Market by End-user
    • 3.1.5 Global Cardiogenic Shock Market by Region
  • 3.2 Global Cardiogenic Shock Market: Treatment Type Analysis
    • 3.2.1 Global Cardiogenic Shock Market by Treatment Type: An Overview
    • 3.2.2 Global Drugs Cardiogenic Shock Market by Value
    • 3.2.3 Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value
    • 3.2.4 Global Other Cardiogenic Shock Market by Value
  • 3.3 Global Cardiogenic Shock Market: End-user Analysis
    • 3.3.1 Global Cardiogenic Shock Market by End-user: An Overview
    • 3.3.2 Global Hospitals & Clinics Cardiogenic Shock Market by Value
    • 3.3.3 Global Specialty Cardiac Centers Cardiogenic Shock Market by Value
    • 3.3.4 Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value
    • 3.3.5 Global Others Cardiogenic Shock Market by Value

4. Regional Market Analysis

  • 4.1 North America Cardiogenic Shock Market: An Analysis
    • 4.1.1 North America Cardiogenic Shock Market: An Overview
    • 4.1.2 North America Cardiogenic Shock Market by Value
    • 4.1.3 North America Cardiogenic Shock Market by Region
    • 4.1.4 The US Cardiogenic Shock Market by Value
    • 4.1.5 Canada Cardiogenic Shock Market by Value
    • 4.1.6 Mexico Cardiogenic Shock Market by Value
  • 4.2 Europe Cardiogenic Shock Market: An Analysis
    • 4.2.1 Europe Cardiogenic Shock Market: An Overview
    • 4.2.2 Europe Cardiogenic Shock Market by Value
    • 4.2.3 Europe Cardiogenic Shock Market by Region
    • 4.2.4 Germany Cardiogenic Shock Market by Value
    • 4.2.5 United Kingdom Cardiogenic Shock Market by Value
    • 4.2.6 France Cardiogenic Shock Market by Value
    • 4.2.7 Italy Cardiogenic Shock Market by Value
    • 4.2.8 Spain Cardiogenic Shock Market by Value
    • 4.2.9 Rest of Europe Cardiogenic Shock Market by Value
  • 4.3 Asia Pacific Cardiogenic Shock Market: An Analysis
    • 4.3.1 Asia Pacific Cardiogenic Shock Market: An Overview
    • 4.3.2 Asia Pacific Cardiogenic Shock Market by Value
    • 4.3.3 Asia Pacific Cardiogenic Shock Market by Region
    • 4.3.4 China Cardiogenic Shock Market by Value
    • 4.3.5 Japan Cardiogenic Shock Market by Value
    • 4.3.6 India Cardiogenic Shock Market by Value
    • 4.3.7 South Korea Cardiogenic Shock Market by Value
    • 4.3.8 Rest of Asia Pacific Cardiogenic Shock Market by Value
  • 4.4 Latin America Cardiogenic Shock Market: An Analysis
    • 4.4.1 Latin America Cardiogenic Shock Market: An Overview
    • 4.4.2 Latin America Cardiogenic Shock Market by Value
  • 4.5 Middle East & Africa Cardiogenic Shock Market: An Analysis
    • 4.5.1 Middle East & Africa Cardiogenic Shock Market: An Overview
    • 4.5.2 Middle East & Africa Cardiogenic Shock Market by Value

5. Impact of COVID-19

  • 5.1 Impact of COVID-19 on Global Cardiogenic Shock Market
  • 5.2 Post COVID-19 Impact on Global Cardiogenic Shock Market

6. Market Dynamics

  • 6.1 Growth Drivers
    • 6.1.1 Increase in the Global Geriatric Population
    • 6.1.2 Increasing Incidence of Heart Disease
    • 6.1.3 Growing Healthcare Expenditure
    • 6.1.4 Growing Prevalence of Sedentary Lifestyle
    • 6.1.5 Rising Awareness and Early Diagnosis
  • 6.2 Challenges
    • 6.2.1 High Cost of Advanced Therapies and Devices
    • 6.2.2 Shortage of Skilled Healthcare Professionals
  • 6.3 Market Trends
    • 6.3.1 Rise in Adoption of Artificial Intelligence
    • 6.3.2 Technological Advancements in Mechanical Circulatory Support (MCS) Devices
    • 6.3.3 Development of Novel Pharmacological Therapies
    • 6.3.4 Rise in Research and Development Activities
    • 6.3.5 Adoption of Minimally Invasive Techniques
    • 6.3.6 Rising Demand for Point-of-Care (POC) Testing

7. Competitive Landscape

  • 7.1 Global Cardiogenic Shock Market Players: Recent Developments

8. Company Profiles

  • 8.1 Abbott
    • 8.1.1 Business Overview
    • 8.1.2 Operating Segments
    • 8.1.3 Business Strategy
  • 8.2 Medtronic plc
    • 8.2.1 Business Overview
    • 8.2.2 Operating Segments
    • 8.2.3 Business Strategy
  • 8.3 Boston Scientific Corporation
    • 8.3.1 Business Overview
    • 8.3.2 Operating Segments
    • 8.3.3 Business Strategy
  • 8.4 AstraZeneca Plc
    • 8.4.1 Business Overview
    • 8.4.2 Business Strategies
  • 8.5 Roche Holdings AG
    • 8.5.1 Business Overview
    • 8.5.2 Operating Segments
    • 8.5.3 Business Strategy
  • 8.6 Bayer AG
    • 8.6.1 Business Overview
    • 8.6.2 Operating Segments
    • 8.6.3 Business Strategy
  • 8.7 Getinge
    • 8.7.1 Business Overview
    • 8.7.2 Operating Segments
    • 8.7.3 Business Strategy
  • 8.8 Johnson & Johnson (Abiomed)
    • 8.8.1 Business Overview
    • 8.8.2 Business Segments
    • 8.8.3 Business Strategy
  • 8.9 Viatris, Inc.
    • 8.9.1 Business Overview
    • 8.9.2 Operating Segments
    • 8.9.3 Business Strategy
  • 8.10 Terumo Corporation
    • 8.10.1 Business Overview
    • 8.10.2 Operating Segments
    • 8.10.3 Business Strategy
  • 8.11 Endo International plc (Par Pharmaceutical)
    • 8.11.1 Business Overview
    • 8.11.2 Operating Segments
    • 8.11.3 Business Strategy
  • 8.12 Windtree Therapeutics, Inc.
    • 8.12.1 Business Overview
    • 8.12.2 Business Strategy
  • 8.13 ZOLL Medical Corporation
    • 8.13.1 Business Overview
    • 8.13.2 Business Strategy

List of Figures

  • Figure 1: Ways to Reduce Cardiogenic Shock Risk
  • Figure 2: Cardiogenic Shock Segmentation
  • Figure 3: Global Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 4: Global Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 5: Global Cardiogenic Shock Market by Treatment Type; 2024 (Percentage, %)
  • Figure 6: Global Cardiogenic Shock Market by End-user; 2024 (Percentage, %)
  • Figure 7: Global Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 8: Global Drugs Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 9: Global Drugs Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 10: Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 11: Global Mechanical Circulatory Support (MCS) Devices Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 12: Global Other Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 13: Global Other Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 14: Global Hospitals & Clinics Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 15: Global Hospitals & Clinics Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 16: Global Specialty Cardiac Centers Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 17: Global Specialty Cardiac Centers Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 18: Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 19: Global Ambulatory Surgical Centers Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 20: Global Others Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 21: Global Others Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 22: North America Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 23: North America Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 24: North America Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 25: The US Cardiogenic Shock Market by Value; 2020-2024 (US$ Billion)
  • Figure 26: The US Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 27: Canada Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 28: Canada Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 29: Mexico Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 30: Mexico Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 31: Europe Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 32: Europe Cardiogenic Shock Market by Value; 2025-2030 (US$ Billion)
  • Figure 33: Europe Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 34: Germany Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 35: Germany Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 36: United Kingdom Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 37: United Kingdom Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 38: France Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 39: France Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 40: Italy Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 41: Italy Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 42: Spain Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 43: Spain Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 44: Rest of Europe Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 45: Rest of Europe Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 46: Asia Pacific Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 47: Asia Pacific Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 48: Asia Pacific Cardiogenic Shock Market by Region; 2024 (Percentage, %)
  • Figure 49: China Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 50: China Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 51: Japan Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 52: Japan Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 53: India Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 54: India Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 55: South Korea Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 56: South Korea Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 57: Rest of Asia Pacific Cardiogenic Shock Market by Value, 2020-2024 (US$ Million)
  • Figure 58: Rest of Asia Pacific Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 59: Latin America Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 60: Latin America Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 61: Middle East & Africa Cardiogenic Shock Market by Value; 2020-2024 (US$ Million)
  • Figure 62: Middle East & Africa Cardiogenic Shock Market by Value; 2025-2030 (US$ Million)
  • Figure 63: Global Percentage Of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
  • Figure 64: Global Trends in Number of Deaths Due to Cardiovascular Diseases; 2019 and 2021 (Million)
  • Figure 65: The US Health Consumption Expenditure as a Percentage of GDP; 2016-2022 (Percentage, %)
  • Figure 66: Global Prevalence of Insufficient Physical Activity Among Adults; 2010, 2022 and 2030 (Percentage, %)
  • Figure 67: Global Artificial Intelligence (AI) in Healthcare Market; 2021-2030 (US$ Billion)
  • Figure 68: Abbott Sales by Segments; 2023 (Percentage, %)
  • Figure 69: Medtronic plc Net Sales by Segment: 2023 (Percentage, %)
  • Figure 70: Boston Scientific Corp. Net Sales by Segment: 2023 (Percentage, %)
  • Figure 71: Roche Holdings AG Sales by Operating Segment; 2024 (Percentage, %)
  • Figure 72: Bayer AG Net Sales by Segment; 2023 (Percentage, %)
  • Figure 73: Getinge Sales by Segment: 2023 (Percentage, %)
  • Figure 74: Johnson & Johnson Sales by Business Segment; 2023 (Percentage, %)
  • Figure 75: Viatris, Inc. Sales by Segment: 2023 (Percentage, %)
  • Figure 76: Terumo Corporation Revenue by Company: 2023 (Percentage, %)
  • Figure 77: Endo International plc Revenue by Company: 2023 (Percentage, %)